Pronethalol

• CAT Number: I004021
• CAS Number: 54-80-8
• Molecular Formula: C15H19NO
• Molecular Weight: 229.32
• Purity: ≥95%
• Synonyms: 1-naphthalen-2-yl-2-(propan-2-ylamino)ethanol
• InChI: InChI=1S/C15H19NO/c1-11(2)16-10-15(17)14-8-7-12-5-3-4-6-13(12)9-14/h3-9,11,15-17H,10H2,1-2H3
• InChIKey: HRSANNODOVBCST-UHFFFAOYSA-N
• SMILES: CC(C)NCC(C1=CC2=CC=CC=C2C=C1)O

Pronethalol ((±)-Pronethalo) is a non-selective β-adrenergic antagonist. Pronethalol is a potent inhibitor of Sox2 expression. Pronethalol protects against and to reverse Digitalis-induced ventricular arrhythmias and limits the cerebral arteriovenous malformation (AVMs)[1][2].
Pronethalol (2, 10, 20 μM) represses EGFP expression in a dose- and time-dependent manner in ReNcell VM cells. Pronethalol (10 μM; 2 days) reduces Sox2 expression to less than 10% after 2 days of treatment[2].
Pronethalol (0.15 mg/g; daily; for 14 days) stabilizes endothelial differentiation, lumen formation and improves cerebral arteriovenous malformation (AVMs) in Mgp–/– mice[2].

Reference

[1]. Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71(4):503-8.
 [Content Brief]

[2]. Jiayi Yao, et al. Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations. J Clin Invest. 2019 Jun 24;129(8):3121-3133.
 [Content Brief]

[3]. Aroesty JM, et al. The effects of a beta-adrenergic blocking agent, pronethalol, on digitalis-induced ventricular arrhythmias. Am Heart J. 1966 Apr;71(4):503-508.